Service d'oncologie médicale

Equipe principale
Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


972 publications

... | 2021 | 2020 | 2019 | ...
2021
 
VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data
Peters S., Dafni U., Perol M., Felip E., Polito L., Pal N., Ton T.G.N., Merritt D., Morris S., Stahel R.A., 2021/05. Annals of Oncology, 32 (5) pp. 687-688.
[DOI][WoS][serval:BIB_3634E1D8C4C5]
Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451.
Owonikoko T.K., Park K., Govindan R., Ready N., Reck M., Peters S., Dakhil S.R., Navarro A., Rodríguez-Cid J., Schenker M. et al., 2021/04/20. Journal of clinical oncology, 39 (12) pp. 1349-1359. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_78F0D04B7BA3]
Suivi téléphonique des patients testés positifs au SARS-CoV-2 au Département d’oncologie du CHUV [Telephone follow-up of SARS-CoV-2 positive patients at the Oncology Department of Lausanne University Hospital]
Jankovic J., Da Silva Lopes A.M., Morez A., Darnac C., Demicheli R., Dalla-Vale M., Lauriers N., Garcia Sanchez J., Bouchaab H., Ninane F. et al., 2021/04/07. Revue medicale suisse, 17 (733) pp. 703-707. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B502B1BCD7F4]
 
Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database.
Wagner A.D., Grothey A., Andre T., Dixon J.G., Wolmark N., Haller D.G., Allegra C.J., de Gramont A., VanCutsem E., Alberts S.R. et al., 2021/04/06. Journal of the National Cancer Institute, 113 (4) pp. 400-407. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_45389DDD78CB]
 
70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age.
Piccart M., van 't Veer L.J., Poncet C., Lopes Cardozo JMN, Delaloge S., Pierga J.Y., Vuylsteke P., Brain E., Vrijaldenhoven S., Neijenhuis P.A. et al., 2021/04. The Lancet. Oncology, 22 (4) pp. 476-488. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AF08B9212168]
Conventional and semi-automatic histopathological analysis of tumor cell content for multigene sequencing of lung adenocarcinoma.
Kazdal D., Rempel E., Oliveira C., Allgäuer M., Harms A., Singer K., Kohlwes E., Ormanns S., Fink L., Kriegsmann J. et al., 2021/04. Translational lung cancer research, 10 (4) pp. 1666-1678. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BA9CF3C21C49]
Impact of COVID-19 on social media as perceived by the oncology community: results from a survey in collaboration with the European Society for Medical Oncology (ESMO) and the OncoAlert Network.
Morgan G., Tagliamento M., Lambertini M., Devnani B., Westphalen B., Dienstmann R., Bozovic-Spasojevic I., Calles A., Criscitiello C., Curioni A. et al., 2021/04. ESMO open, 6 (2) p. 100104. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_342B627B94E0]
OncoAlert Round Table Discussions: The Global COVID-19 Experience.
Morgan G., de Azambuja E., Punie K., Ades F., Heinrich K., Personeni N., Rahme R., Ferrara R., Pels K., Garassino M. et al., 2021/04. JCO global oncology, 7 pp. 455-463. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0A9B77FD6F7E]
 
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro Antonio, Jänne Pasi A., Mok Tony, Peters Solange, 2021/04. Nature Cancer, 2 (4) pp. 377-391.
[DOI][WoS][serval:BIB_67E3EEBBA705]
 
The Promising Evolution of Targeted Therapeutic Strategies in Cancer.
Peters S., Mok T., Passaro A., Jänne P.A., 2021/04. Cancer discovery, 11 (4) pp. 810-814. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C4A6BE00E890]
 
A Blood-based Assay for Assessment of Tumor Mutational Burden in First-line Metastatic NSCLC Treatment: Results from the MYSTIC Study.
Si H., Kuziora M., Quinn K.J., Helman E., Ye J., Liu F., Scheuring U., Peters S., Rizvi N.A., Brohawn P.Z. et al., 2021/03/15. Clinical cancer research, 27 (6) pp. 1631-1640. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1004EC355F9F]
Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1.
Sflomos G., Battista L., Aouad P., De Martino F., Scabia V., Stravodimou A., Ayyanan A., Ifticene-Treboux A., RLS, Bucher P. et al., 2021/03/05. EMBO molecular medicine, 13 (3) pp. e13180. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7FB2372AC0AF]
Abscopal effect in a patient with malignant pleural mesothelioma treated with palliative radiotherapy and pembrolizumab.
Mampuya W.A., Bouchaab H., Schaefer N., Kinj R., La Rosa S., Letovanec I., Ozsahin M., Bourhis J., Coukos G., Peters S. et al., 2021/03. Clinical and translational radiation oncology, 27 pp. 85-88. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C82F89BA6EDB]
 
ESMO pays tribute to Professor José Baselga.
Peters S., Tabernero J., Cervantes A., Banerjee S., Giuliani R., Lordick F., 2021/03. Immuno-oncology technology, 9 p. 100027. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_088E6B728DE3]
Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
Gandara D., Reck M., Moro-Sibilot D., Mazieres J., Gadgeel S., Morris S., Cardona A., Mendus D., Ballinger M., Rittmeyer A. et al., 2021/03. Journal for immunotherapy of cancer, 9 (3) pp. e001882. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_475BFAD3DFC0]
Severity of COVID-19 in patients with lung cancer: evidence and challenges.
Passaro A., Bestvina C., Velez Velez M., Garassino M.C., Garon E., Peters S., 2021/03. Journal for immunotherapy of cancer, 9 (3) pp. e002266. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_65ACCD8023E1]
 
Strength in numbers: predicting response to checkpoint inhibitors from large clinical datasets.
Stenzinger A., Kazdal D., Peters S., 2021/02/04. Cell, 184 (3) pp. 571-573. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F9D89455E11F]
 
Image-guided percutaneous cryoablation of unresectable sacrococcygeal chordoma: Feasibility and outcome in a selected group of patients with long term follow-up.
Cherix S., Traverso A., Bazan A.A., Gallusser N., Heutschi-Ozturk H., Abou-Khalil S., Goetti P., Letovanec I., Montemurro M., Bize P., 2021/02. Journal of surgical oncology, 123 (2) pp. 497-504. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3341523072BD]
Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology.
Özdemir B.C., 2021/02. Journal for immunotherapy of cancer, 9 (2) pp. e002220. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_838DD59A4F97]
Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
Mok T., Peters S., Camidge D.R., Noé J., Gadgeel S., Ou S.I., Kim D.W., Konopa K., Pozzi E., Liu T. et al., 2021/02. Journal of thoracic oncology, 16 (2) pp. 259-268. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C28D20FEA475]
Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
Moi L., Bouchaab H., Mederos N., Nguyen-Ngoc T., Perreau M., Fenwick C., Vaucher J., Sempoux C., Peters S., Obeid M., 2021/02. Journal of thoracic oncology, 16 (2) pp. 318-326. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3FFE3BA356BB]
Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma.
Dunet V., Halkic N., Sempoux C., Demartines N., Montemurro M., Prior J.O., Schmidt S., 2021/02. European radiology, 31 (2) pp. 992-1001. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E6D90FEBC90D]
 
Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14).
Peters S., Felip E., Dafni U., Tufman A., Guckenberger M., Álvarez R., Nadal E., Becker A., Vees H., Pless M. et al., 2021/02. Journal of thoracic oncology, 16 (2) pp. 278-288. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8512C8B4A7E1]
 
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.
Baas P., Scherpereel A., Nowak A.K., Fujimoto N., Peters S., Tsao A.S., Mansfield A.S., Popat S., Jahan T., Antonia S. et al., 2021/01/30. Lancet, 397 (10272) pp. 375-386. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1562B775FCBE]
Neurologie [Recent Advances in Neurology]
Anichini A., Salvioni Chiabotti P., Bally J., Castro Jimenez M., Démonet J.F., Di Virgilio G., Hirt L., Hottinger A., Kuntzer T., Michel P. et al., 2021/01/27. Revue medicale suisse, 17 (723) pp. 196-200. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_66C893415E17]
Oncologie [2020 oncology update]
Dei Tos G., Galli Vareia I., Huber A., Wolf B., Diciolla A., Herrera Gomez R.G., Wagner D., Digklia A., Bouchaab H., Cristina V. et al., 2021/01/27. Revue medicale suisse, 17 (723) pp. 201-205. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_25D6152EB267]
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma.
Budczies J., Kirchner M., Kluck K., Kazdal D., Glade J., Allgäuer M., Kriegsmann M., Heußel C.P., Herth F.J., Winter H. et al., 2021/01/11. Oncoimmunology, 10 (1) p. 1860586. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9EBDF473F7F9]
 
Cancer Research in 2021
Peters Solange, Zhan Qimin, Loi Sherene, Oni Tobiloba, 2021/01/11. Cancer Cell, 39 (1) pp. 1-2.
[WoS][serval:BIB_5482D281AE67]
 
Advanced Gastric Cancer: Current Treatment Landscape and a Future Outlook for Sequential and Personalized Guide: Swiss Expert Statement Article.
Siebenhüner A.R., De Dosso S., Helbling D., Astaras C., Szturz P., Moosmann P., Pederiva S., Winder T., Von Burg P., Borner M., 2021. Oncology research and treatment, 44 (9) pp. 485-494. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0FE58A54D26A]
 
Androgen Signaling in the Tumor Microenvironment
Özdemir Berna C., 2021. pp. 169-183 dans Advances in Experimental Medicine and Biology, Springer International Publishing.
[DOI][WoS][Pmid][serval:BIB_B1653EE55D76]
 
Anti-GD1b and anti-GM1 positive, acute inflammatory demyelinating polyneuropathy associated with advanced ovarian carcinoma: A case report
Frutiger Julie, Liapi Aikaterini, Hastir Delfyne, Hottinger Andreas, Sarivalasis Apostolos, 2021. International Journal of Case Reports and Images, 12 p. 1.
[DOI][serval:BIB_AD6F8ADA616F]
Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
Zimmerli A., Monti M., Fenwick C., Eckerle I., Beigelman-Aubry C., Pellaton C., Jaton K., Dumas D., Stamm G.M., Infanti L. et al., 2021. Frontiers in immunology, 12 p. 613502. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_AE27E1EE2E3C]
Case Report: Vasculitis Triggered by SIRT in a Patient With Previously Untreated Cholangiocarcinoma.
Stamatiou A., Jankovic J., Szturz P., Fasquelle F., Duran R., Schaefer N., Diciolla A., Digklia A., 2021. Frontiers in oncology, 11 p. 755750. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_441991FCB38E]
 
Diagnostic Surveillance of High-Grade Gliomas: Towards Automated Change Detection Using Radiology Report Classification
Tommaso Di Noto, Chirine Atat, Eduardo Gamito Teiga, Monika Hegi, Andreas Hottinger, Meritxell Bach Cuadra, Patric Hagmann, Jonas Richiardi, 2021. dans Machine Learning and Principles and Practice of Knowledge Discovery in Databases, Springer International Publishing.
[DOI][serval:BIB_CD112344008E]
Efficacy and Safety of Tumor Treating Fields (TTFields) in Elderly Patients with Newly Diagnosed Glioblastoma: Subgroup Analysis of the Phase 3 EF-14 Clinical Trial.
Ram Z., Kim C.Y., Hottinger A.F., Idbaih A., Nicholas G., Zhu J.J., 2021. Frontiers in oncology, 11 p. 671972. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7B80528610A1]
 
Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis.
Dafni U., Martín-Lluesma S., Balint K., Tsourti Z., Vervita K., Chenal J., Coukos G., Zaman K., Sarivalasis A., Kandalaft L.E., 2021/01. European journal of cancer, 142 pp. 63-82. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D084831A838B]
 
Expert Discussion: Immunotherapy in Breast Cancer – Ready for Prime Time?
Rinnerthaler Gabriel, Müller Volkmar, Balic Marija, Zaman Khalil, Dieci Maria Vittoria, 2021. Breast Care, 16 (2) pp. 188-191.
[DOI][WoS][serval:BIB_CD588D5E962E]
Impact of an enhanced recovery after surgery pathway on thoracoscopic lobectomy outcomes in non-small cell lung cancer patients: a propensity score-matched study.
Forster C., Doucet V., Perentes J.Y., Abdelnour-Berchtold E., Zellweger M., Faouzi M., Bouchaab H., Peters S., Marcucci C., Krueger T. et al., 2021/01. Translational lung cancer research, 10 (1) pp. 93-103. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CE8DA5ECA070]
Lurbinectedin in Refractory Diffuse Malignant Peritoneal Mesothelioma: Report of Two Cases.
Gros L., Szturz P., Diciolla A., Kirchner V., Peters S., Schaefer N., Hubner M., Digklia A., 2021. Frontiers in oncology, 11 p. 704295. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E9DC9323568E]
Meta-Analysis on Induction Chemotherapy in Locally Advanced Nasopharyngeal Carcinoma.
Mané M., Benkhaled S., Dragan T., Paesmans M., Beauvois S., Lalami Y., Szturz P., Gaye P.M., Vermorken J.B., Van Gestel D., 2021/01. The oncologist, 26 (1) pp. e130-e141. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6E0B9B9E5AF3]
 
MRI and <sup>18</sup>FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial.
Wirsching H.G., Roelcke U., Weller J., Hundsberger T., Hottinger A.F., von Moos R., Caparrotti F., Conen K., Remonda L., Roth P. et al., 2021/01/01. Clinical cancer research, 27 (1) pp. 179-188. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9DF2F9C55BFB]
 
Optimizing oral targeted anticancer therapies study for patients with solid cancer: Protocol for a randomized controlled medication adherence program along with systematic collection and modeling of pharmacokinetic and pharmacodynamic data.
Bandiera C., Cardoso E., Locatelli I., Digklia A., Zaman K., Diciolla A., Cristina V., Stravodimou A., Lopez V.A., Dolcan A. et al., 2021. JMIR research protocols, 10 (6) pp. e30090. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7657CD7990C9]
 
Panitumumab as an effective maintenance treatment in metastatic squamous cell carcinoma of the head and neck.
Herrera Gómez R.G., Saleh K., Mayache L., Iacob M., Baste N., Even C., 2021/01. Oral oncology, 112 p. 104984. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8FAA5CA91888]
 
Pilot Testing of a Nurse-Led Basic Symptom Self-management Support for Patients Receiving First-Line Systemic Outpatient Anticancer Treatment: A Cluster-Randomized Study (Symptom Navi Pilot Study).
Bana M., Ribi K., Peters S., Kropf-Staub S., Näf E., Zürcher-Florin S., Stoffel B., Blaeuer C., Borner M., Malin D. et al., 2021. Cancer nursing, 44 (6) pp. E687-E702. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0DB30006FEDE]
So-Called Serous Carcinoma of the Uterine Cervix with BRCA2 Mutation: Case Report and Review of the Literature.
Herrera Gómez R.G., Hastir D., Liapi A., Dolcan A., Herrera F.G., Mathevet P., Sarivalasis A., 2021. Case reports in oncology, 14 (3) pp. 1792-1798. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E2E089A99CB8]
Surgical Strategy Based on Radiological 3D Reconstruction in a Giant Metastatic Neuroendocrine Tumor of the Pancreas: A Case Report of an Interdisciplinary Approach.
Hess G.F., Soysal S.D., Nicolas G., Bolli M., Zech C.J., Tzankov A., Christ E., Montemurro M., Kollmar O., 2021. Case reports in surgery, 2021 p. 8811155. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_6F69C4E6EECF]
 
Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic.
Gatson NTN, Barnholtz-Sloan J., Drappatz J., Henriksson R., Hottinger A.F., Hinoul P., Kruchko C., Puduvalli V.K., Tran D.D., Wong E.T. et al., 2021. Frontiers in oncology, 11 p. 679702. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3821A19B0477]
 
Tumor Treating Fields for Glioblastoma Therapy During the COVID-19 Pandemic.
Gatson NTN, Barnholtz-Sloan J., Drappatz J., Henriksson R., Hottinger A.F., Hinoul P., Kruchko C., Puduvalli V.K., Tran D.D., Wong E.T. et al., 2021. Frontiers in oncology, 11 p. 679702. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_45FA8B6C595F]
 
Utilisation du cannabis à visée médicale. Dix ans d’expérience suisse
Mapi Fleury, 2021. Journal de Pharmacie Clinique, 40 (4) pp. 173-182. Peer-reviewed.
[DOI][serval:BIB_7A4DF84742A9]
2020
Oligometastatic Disease Management: Finding the Sweet Spot.
Szturz P., Nevens D., Vermorken J.B., 2020/12/22. Frontiers in oncology, 10 p. 617793. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_72F5AC8F1919]
 
Phase I Trial of Debio 1143, an Antagonist of Inhibitor of Apoptosis Proteins, Combined with Cisplatin Chemoradiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
Le Tourneau C., Tao Y., Gomez-Roca C., Cristina V., Borcoman E., Deutsch E., Bahleda R., Calugaru V., Modesto A., Rouits E. et al., 2020/12/15. Clinical cancer research, 26 (24) pp. 6429-6436. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2A8394CFA639]
 
Targeting KRAS-Mutant Non-Small-Cell Lung Cancer: One Mutation at a Time, With a Focus on KRAS G12C Mutations.
Burns T.F., Borghaei H., Ramalingam S.S., Mok T.S., Peters S., 2020/12/10. Journal of clinical oncology, 38 (35) pp. 4208-4218. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1C13F7E17D98]
A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Popat S., Curioni-Fontecedro A., Dafni U., Shah R., O'Brien M., Pope A., Fisher P., Spicer J., Roy A., Gilligan D. et al., 2020/12. Annals of oncology, 31 (12) pp. 1734-1745. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0FC8052F2621]
 
Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment.
Subbiah V., Paz-Ares L., Besse B., Moreno V., Peters S., Sala M.A., López-Vilariño J.A., Fernández C., Kahatt C., Alfaro V. et al., 2020/12. Lung cancer, 150 pp. 90-96. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4CA435908C3F]
 
Behandlung des fortgeschrittenen Prostatakarzinoms
Templeton Arnoud J, Amram Marie-Laure, Berthold Dominik, Beyer Jrg, Blaser Samuel, Burger Irene A., Eberli Daniel, Gillessen Sommer Silke, Grobholz Rainer, Kng Marc et al., 2020/12/01. Swiss Medical Forum ‒ Schweizerisches Medizin-Forum. Peer-reviewed..
[DOI][serval:BIB_FF54607A317C]
 
Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis.
Özdemir B.C., Latifyan S., Perreau M., Fenwick C., Alberio L., Waeber G., Spertini F., de Leval L., Michielin O., Obeid M., 2020/12. Annals of oncology, 31 (12) pp. 1775-1778. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DC85C792AD0C]
 
Disturbed mitochondrial dynamics in CD8<sup>+</sup> TILs reinforce T cell exhaustion.
Yu Y.R., Imrichova H., Wang H., Chao T., Xiao Z., Gao M., Rincon-Restrepo M., Franco F., Genolet R., Cheng W.C. et al., 2020/12. Nature immunology, 21 (12) pp. 1540-1551. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_89908ED24FA7]
Evaluating Brightness and Spectral Properties of Click Beetle and Firefly Luciferases Using Luciferin Analogues: Identification of Preferred Pairings of Luciferase and Substrate for In Vivo Bioluminescence Imaging.
Zambito G., Gaspar N., Ridwan Y., Hall M.P., Shi C., Kirkland T.A., Encell L.P., Löwik C., Mezzanotte L., 2020/12. Molecular imaging and biology, 22 (6) pp. 1523-1531. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_1FD4332877FF]
Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians.
Chazan G., Franchini F., Alexander M., Banerjee S., Mileshkin L., Blinman P., Zielinski R., Karikios D., Pavlakis N., Peters S. et al., 2020/12. ESMO open, 5 (6) pp. e001090. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EBC36A1764E1]
Dépistage du cancer pulmonaire en Suisse : Qui ? Comment ? Quand ? [Lung cancer screening in Switzerland : Who ? How ? When ?]
Casutt A., Lovis A., Selby K., Noirez L., Peters S., Beigelman-Aubry C., Krueger T., Soccal P.M., Von Garnier C., 2020/11/18. Revue medicale suisse, 16 (715) pp. 2224-2226. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3E98E6494DEA]
Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy.
Hamzic S., Aebi S., Joerger M., Montemurro M., Ansari M., Amstutz U., Largiadèr C., 2020/11/16. Swiss medical weekly, 150 pp. w20375. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_68098FEC0EB5]
 
The METeoric rise of MET in lung cancer.
Friedlaender A., Drilon A., Banna G.L., Peters S., Addeo A., 2020/11/15. Cancer, 126 (22) pp. 4826-4837. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_392CF01A9189]
Computer-assisted textual analysis of free-text comments in the Swiss Cancer Patient Experiences (SCAPE) survey.
Arditi C., Walther D., Gilles I., Lesage S., Griesser A.C., Bienvenu C., Eicher M., Peytremann-Bridevaux I., 2020/11/10. BMC health services research, 20 (1) p. 1029. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6A512FB4EFBF]
COVID-19 and Cancer: Current Challenges and Perspectives.
Bakouny Z., Hawley J.E., Choueiri T.K., Peters S., Rini B.I., Warner J.L., Painter C.A., 2020/11/09. Cancer cell, 38 (5) pp. 629-646. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5F36B8AB6875]
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience.
Trama A., Proto C., Whisenant J.G., Torri V., Cortellini A., Michielin O., Barlesi F., Dingemans A.C., Van Meerbeeck J., Pancaldi V. et al., 2020/11/09. Cancer cell, 38 (5) pp. 602-604. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6F92D71268C4]
 
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.
Passaro A., Stenzinger A., Peters S., 2020/11/09. Cancer cell, 38 (5) pp. 624-625. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BE5AFDD22C20]
Communication des risques en santé : revue de littérature et recommandations pour la pratique clinique. [Risk communication in healthcare: literature review and recommendations for clinical practice]
Durand M.A., Selby K., Bodenmann P., Zaman K., Ducros C., Cornuz J., 2020/11/04. Revue medicale suisse, 16 (713) pp. 2092-2098. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_CF77AE92DA7F]
Dépistage du cancer du poumon : que dire à nos patient·e·s en attendant un programme organisé ? [Lung cancer screening: what can we tell our patients while we await a screening program ?]
Selby K., Gubelmann R., Lovis A., Bulliard J.L., Beigelman-Aubry C., Casutt A., Peters S., Krueger T., Von Garnier C., Cornuz J., 2020/11/04. Revue medicale suisse, 16 (713) pp. 2086-2091. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FC6D286D8FE3]
Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer.
Mederos N., Friedlaender A., Peters S., Addeo A., 2020/11. ESMO open, 5 (Suppl 4) pp. e000796. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BA2B4BF60C64]
 
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
McNamara M.G., Lopes A., Wasan H., Malka D., Goldstein D., Shannon J., Okusaka T., Knox J.J., Wagner A.D., André T. et al., 2020/11. Journal of hepatology, 73 (5) pp. 1109-1117. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0EE5ED2AA22A]
 
Physical approaches to treat glioblastoma.
Latifyan S., de Micheli R., Hottinger A.F., 2020/11. Current opinion in oncology, 32 (6) pp. 640-649. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_80B7782807AE]
Transarterial Radioembolization for the Treatment of Advanced Hepatocellular Carcinoma Invading the Right Atrium.
Girardet R., Boughdad S., Digklia A., Beigelman C., Meyer M., Schaefer N., Vermersch M., Hocquelet A., Tsoumakidou G., Denys A. et al., 2020/11. Cardiovascular and interventional radiology, 43 (11) pp. 1712-1715. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_026A056D5150]
Precision Oncology and Gender Medicine – Moving Forward, Slowly but Surely
Özdemir Berna, Wagner Anna Dorothea, 2020/10/12. healthbook TIMES Oncology Hematology 5.
[URN][DOI][serval:BIB_1452A08F64C5]
Prise en charge par l’ORL des mélanomes cutanés cervico-faciaux [ENT management of head and neck cutaneous melanoma]
Jaballah Vinckenbosch P., Litzistorf Y., Gaide O., Özdemir B.C., Michielin O., Reinhard A., 2020/10/07. Revue medicale suisse, 16 (709) pp. 1853-1859. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_844B37B67CDB]
 
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial.
Peters S., Danson S., Hasan B., Dafni U., Reinmuth N., Majem M., Tournoy K.G., Mark M.T., Pless M., Cobo M. et al., 2020/10. Journal of thoracic oncology, 15 (10) pp. 1647-1656. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3774693F09A5]
 
Consensus paper: current state of first- and second-line therapy in advanced clear-cell renal cell carcinoma.
Goebell P.J., Ivanyi P., Bedke J., Bergmann L., Berthold D., Boegemann M., Busch J., Doehn C., Krege S., Retz M. et al., 2020/10. Future oncology, 16 (29) pp. 2307-2328. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_467B24623EBB]
 
Editorial overview: Pharmaceutical biotechnology: new frontiers in cancer immunotherapy.
Kandalaft L.E., Graciotti M., 2020/10. Current opinion in biotechnology, 65 pp. iii-v. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_6F4B29364362]
 
Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers.
Martinez Chanza N., Werner L., Plimack E., Yu E.Y., Alva A.S., Crabb S.J., Powles T., Rosenberg J.E., Baniel J., Vaishampayan U.N. et al., 2020/10. European urology oncology, 3 (5) pp. 671-679. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5983599BD430]
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus.
Curigliano G., Banerjee S., Cervantes A., Garassino M.C., Garrido P., Girard N., Haanen J., Jordan K., Lordick F., Machiels J.P. et al., 2020/10. Annals of oncology, 31 (10) pp. 1320-1335. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_957BAED3FD8F]
 
Overcoming frailty in recurrent and metastatic head and neck cancer.
Szturz P., Vermorken J.B., 2020/10. Oral oncology, 109 p. 104636. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_234F84438D93]
 
Utilization of COVID-19 Treatments and Clinical Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
Rivera D.R., Peters S., Panagiotou O.A., Shah D.P., Kuderer N.M., Hsu C.Y., Rubinstein S.M., Lee B.J., Choueiri T.K., de Lima Lopes G. et al., 2020/10. Cancer discovery, 10 (10) pp. 1514-1527. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2286AC0B4000]
Hypertension artérielle et cancer : une relation étroite à ne pas oublier [Hypertension and cancer : a close relationship to remember!]
Bocchi F., Jankovic J., Wuerzner G., 2020/09/16. Revue medicale suisse, 16 (706) pp. 1680-1683. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_287E2B1A62E4]
 
ESMO MANAGEMENT AND TREATMENT ADAPTED RECOMMENDATIONS IN THE COVID-19 ERA: HEAD AND NECK CANCERS
Bossi P., Piazza C., Szturz P., Balermpas P., Machiels J.P., 2020/09/02..
[serval:BIB_D05E642A4C5A]
 
Comparison of robust to standardized CT radiomics models to predict overall survival for non-small cell lung cancer patients.
Vuong D., Bogowicz M., Denzler S., Oliveira C., Foerster R., Amstutz F., Gabryś H.S., Unkelbach J., Hillinger S., Thierstein S. et al., 2020/09. Medical physics, 47 (9) pp. 4045-4053. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_547DEC2C051E]
 
Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
Seban R.D., Moya-Plana A., Antonios L., Yeh R., Marabelle A., Deutsch E., Schwartz L.H., Gómez RGH, Saenger Y., Robert C. et al., 2020/09. European journal of nuclear medicine and molecular imaging, 47 (10) pp. 2301-2312. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_86BBC6AFEB18]
Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapy.
Wagner A.D., 2020/09. ESMO open, 5 (5) pp. e000770. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8A7C30FCAAE3]
 
The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.
Stravodimou A., Voutsadakis I.A., 2020/09. Anticancer research, 40 (9) pp. 4829-4841. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1228E171873C]
 
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
Sholl L.M., Hirsch F.R., Hwang D., Botling J., Lopez-Rios F., Bubendorf L., Mino-Kenudson M., Roden A.C., Beasley M.B., Borczuk A. et al., 2020/09. Journal of thoracic oncology, 15 (9) pp. 1409-1424. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_CD51CF3631B2]
Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis.
Doms J., Prior J.O., Peters S., Obeid M., 2020/09. Annals of oncology, 31 (9) pp. 1273-1275. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_36FA44B46F63]
NanoBiT System and Hydrofurimazine for Optimized Detection of Viral Infection in Mice-A Novel in Vivo Imaging Platform.
Gaspar N., Zambito G., Dautzenberg IJC, Cramer S.J., Hoeben R.C., Lowik C., Walker J.R., Kirkland T.A., Smith T.P., van Weerden W.M. et al., 2020/08/15. International journal of molecular sciences, 21 (16). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F4F6102BC551]
 
Further clinical interpretation and implications of KEYNOTE-048 findings.
Szturz P., Vermorken J.B., 2020/08/08. Lancet, 396 (10248) p. 379. Peer-reviewed.
[DOI][Pmid][serval:BIB_F19E1A6BA09F]
 
Global Perspective: Head and Neck Cancers.
Szturz P., Vermorken J.B., 2020/08/05. dans ASCO-SEP 7th Edition., Benjamin P. Levy.
[serval:BIB_2C97F92DDB47]
Guillain-Barré syndrome after adoptive cell therapy with tumor-infiltrating lymphocytes.
Orcurto A., Hottinger A., Wolf B., Navarro Rodrigo B., Ochoa de Olza M., Auger A., Kuntzer T., Comte D., Zimmer V., Gannon P. et al., 2020/08. Journal for immunotherapy of cancer, 8 (2) pp. e001155. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C930B13A53AD]
Oncological care organisation during COVID-19 outbreak.
Onesti C.E., Rugo H.S., Generali D., Peeters M., Zaman K., Wildiers H., Harbeck N., Martin M., Cristofanilli M., Cortes J. et al., 2020/08. ESMO open, 5 (4) pp. e000853. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D873A1F1DC6A]
 
Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort.
Schmid S., Mauti L.A., Friedlaender A., Blum V., Rothschild S.I., Bouchaab H., Frösch P., Britschgi C., König D., Wannesson L. et al., 2020/08. Cancer immunology, immunotherapy, 69 (8) pp. 1605-1613. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9C822C4B4241]
 
Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position.
Levy A., Wagner A.D., Chargari C., Moehler M., Verheij M., Durand-Labrunie J., Kissel M., Chirat E., Burtin P., Ducreux M. et al., 2020/08. European journal of cancer, 135 pp. 103-112. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DAD4904FA6D1]
 
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B., Sarivalasis A., Lozano L.E., Wyss T., Inoges S., de Vries IJM, Dartiguenave F., Jichlinski P., Derrè L., Coukos G. et al., 2020/08. European journal of cancer, 135 pp. 173-182. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D30511CA8B6D]
Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer.
Ürün Y., Hussain S.A., Bakouny Z., Castellano D., Kılıçkap S., Morgan G., Mckay R.R., Pels K., Schmidt A., Doroshow D.B. et al., 2020/08. JCO global oncology, 6 pp. 1248-1257. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8FE7781B5AAE]
Translating KEYNOTE-048 into practice recommendations for head and neck cancer.
Szturz P., Vermorken J.B., 2020/08. Annals of translational medicine, 8 (15) p. 975. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EE9D83DE88C9]
 
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
Mok T., Camidge D.R., Gadgeel S.M., Rosell R., Dziadziuszko R., Kim D.W., Pérol M., Ou S.I., Ahn J.S., Shaw A.T. et al., 2020/08. Annals of oncology, 31 (8) pp. 1056-1064. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_903A82E6C2F5]
Urgent Considerations for the Neuro-oncologic Treatment of Patients with Gliomas During the COVID-19 Pandemic.
Mohile N.A., Blakeley J.O., Gatson NTN, Hottinger A.F., Lassman A.B., Ney D.E., Olar A., Schiff D., Shih H.A., Strowd R. et al., 2020/07/22. Neuro-oncology, 22 (7) pp. 912-917. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8F1C1BE3C2E7]
 
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.
Rudin C.M., Awad M.M., Navarro A., Gottfried M., Peters S., Csőszi T., Cheema P.K., Rodriguez-Abreu D., Wollner M., Yang J.C. et al., 2020/07/20. Journal of clinical oncology, 38 (21) pp. 2369-2379. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F1348AF21FC5]
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Garassino M.C., Whisenant J.G., Huang L.C., Trama A., Torri V., Agustoni F., Baena J., Banna G., Berardi R., Bettini A.C. et al., 2020/07. The Lancet. Oncology, 21 (7) pp. 914-922. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7ACA42FE2BEB]
Gender gap: surveying the world for tomorrow.
Garrido P., Tsang J., Peters S., 2020/07. ESMO open, 5 (4) pp. e000805. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6685CD3391ED]
Oncology during the COVID-19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients.
Tsamakis K., Gavriatopoulou M., Schizas D., Stravodimou A., Mougkou A., Tsiptsios D., Sioulas V., Spartalis E., Sioulas A.D., Tsamakis C. et al., 2020/07. Oncology letters, 20 (1) pp. 441-447. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B80FE975C205]
 
Population Pharmacokinetics of Erlotinib in Patients With Non-small Cell Lung Cancer: Its Application for Individualized Dosing Regimens in Older Patients.
Cardoso E., Guidi M., Khoudour N., Boudou-Rouquette P., Fabre E., Tlemsani C., Arrondeau J., Goldwasser F., Vidal M., Schneider M.P. et al., 2020/07. Clinical therapeutics, 42 (7) pp. 1302-1316. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C945C7298567]
Testing for COVID-19 in lung cancer patients.
Passaro A., Peters S., Mok TSK, Attili I., Mitsudomi T., de Marinis F., 2020/07. Annals of oncology, 31 (7) pp. 832-834. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6FD1FFB724F7]
Treatment Guidance for Patients With Lung Cancer During the Coronavirus 2019 Pandemic.
Dingemans A.C., Soo R.A., Jazieh A.R., Rice S.J., Kim Y.T., Teo LLS, Warren G.W., Xiao S.Y., Smit E.F., Aerts J.G. et al., 2020/07. Journal of thoracic oncology, 15 (7) pp. 1119-1136. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E3CFA6233B0E]
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Kuderer N.M., Choueiri T.K., Shah D.P., Shyr Y., Rubinstein S.M., Rivera D.R., Shete S., Hsu C.Y., Desai A., de Lima Lopes G. et al., 2020/06/20. Lancet, 395 (10241) pp. 1907-1918. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B3D837E39CC4]
Engineering Strategies to Enhance TCR-Based Adoptive T Cell Therapy.
Rath J.A., Arber C., 2020/06/18. Cells, 9 (6) p. 1485. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_53031F025A7F]
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration.
Whisenant J.G., Trama A., Torri V., De Toma A., Viscardi G., Cortellini A., Michielin O., Barlesi F., Dingemans A.C., Van Meerbeeck J. et al., 2020/06/08. Cancer cell, 37 (6) pp. 742-745. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F9BFA1700A3B]
The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer.
Rubinstein S.M., Steinharter J.A., Warner J., Rini B.I., Peters S., Choueiri T.K., 2020/06/08. Cancer cell, 37 (6) pp. 738-741. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_B286806D4653]
A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults.
Roth P., Hottinger A.F., Hundsberger T., Läubli H., Schucht P., Reinert M., Mamot C., Roelcke U., Pesce G., Hofer S. et al., 2020/06/01. Swiss medical weekly, 150 pp. w20256. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_FDC3A4EA3596]
 
Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy.
Haanen J., Ernstoff M.S., Wang Y., Menzies A.M., Puzanov I., Grivas P., Larkin J., Peters S., Thompson J.A., Obeid M., 2020/06. Annals of oncology, 31 (6) pp. 724-744. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4BA2439C7A4C]
Challenges in lung cancer therapy during the COVID-19 pandemic.
Calabrò L., Peters S., Soria J.C., Di Giacomo A.M., Barlesi F., Covre A., Altomonte M., Vegni V., Gridelli C., Reck M. et al., 2020/06. The Lancet. Respiratory medicine, 8 (6) pp. 542-544. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C8A0BEA4C21E]
 
Choice of first line systemic treatment in pancreatic cancer among national experts.
Glatzer M., Horber D., Montemurro M., Winterhalder R., Inauen R., Berger M.D., Pestalozzi B., Pederiva S., Pless M., Putora P.M., 2020/06. Pancreatology, 20 (4) pp. 686-690. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C847DAC2A00B]
Commentary to "Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials" (Galvano et al. J Bone Oncol 2019; 18:100252).
Gonzalez-Rodriguez E., Aubry-Rozier B., Stoll D., Zaman K., Lamy O., 2020/06. Journal of bone oncology, 22 p. 100294. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4DEC0E9E3BD0]
 
Describing adverse events in Swiss hospitalized oncology patients using the Global Trigger Tool.
Gerber A., Da Silva Lopes A., Szüts N., Simon M., Ribordy-Baudat V., Ebneter A., Perrinjaquet C., Gaignard M.E., Nicodet D., Betticher D. et al., 2020/06. Health science reports, 3 (2) pp. e160. Peer-reviewed.
[DOI][Pmid][serval:BIB_FAD287FC4FA7]
ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer.
Passaro A., Addeo A., Von Garnier C., Blackhall F., Planchard D., Felip E., Dziadziuszko R., de Marinis F., Reck M., Bouchaab H. et al., 2020/06. ESMO open, 5 (Suppl 3). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_90B1DD0DAAFD]
 
Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer.
Peters S., Shaw A.T., Besse B., Felip E., Solomon B.J., Soo R.A., Bearz A., Gadgeel S.M., Lin C.C., Kao S. et al., 2020/06. Lung cancer, 144 pp. 10-19. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_BF557DCD51CA]
Interventional oncology at the time of COVID-19 pandemic: Problems and solutions.
Denys A., Guiu B., Chevallier P., Digklia A., de Kerviler E., de Baere T., 2020/06. Diagnostic and interventional imaging, 101 (6) pp. 347-353. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BF6D342B5BAB]
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
Haanen J., Ernstoff M., Wang Y., Menzies A., Puzanov I., Grivas P., Larkin J., Peters S., Thompson J., Obeid M., 2020/06. Journal for immunotherapy of cancer, 8 (1) pp. e000604. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D60E64350838]
Cancer du poumon à petites cellules : prise en charge et nouveautés [Small-cell lung cancer: management and novelties]
Abdelhamid K., Kakourou A., Degrauwe N., Nikolopoulou A., Bouchaab H., Peters S., Nguyen-Ngoc T., Mederos N., 2020/05/27. Revue medicale suisse, 16 (695) pp. 1079-1085. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_3F2FC3093CB5]
Cancer du sein: perspectives de médecine intégrative [Breast cancer: perspectives from integrative medicine]
Stravodimou A., Zurron N., Fleury M., Stanic J., Ramos Chapuis M., Eicher M., Berna C., Zaman K., 2020/05/27. Revue medicale suisse, 16 (695) pp. 1102-1105. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0DCBDD7111BC]
Mélanome localement avancé et métastatique : nouveautés [Locally advanced and metastatic melanoma : novelties]
Huber A., Latifyan S., Nikolopoulou A., Homicsko K., Berthod G., Michielin O., Özdemir B.C., 2020/05/27. Revue medicale suisse, 16 (695) pp. 1092-1097. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_E5DDB348D97F]
Une période de craintes et de défis : vers un monde meilleur ?
Dietrich P.Y., Aapro M., Peters S., 2020/05/27. Revue medicale suisse, 16 (695) pp. 1071-1072. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BD0A61CB32C6]
 
Increased Risk of Multiple Spontaneous Vertebral Fractures at Denosumab Discontinuation Must Be Taken Into Account.
Gonzalez-Rodriguez E., Aubry-Rozier B., Stoll D., Zaman K., Lamy O., 2020/05/10. Journal of clinical oncology, 38 (14) pp. 1641-1642. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_27D8857FE1F7]
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.
Rizvi N.A., Cho B.C., Reinmuth N., Lee K.H., Luft A., Ahn M.J., van den Heuvel M.M., Cobo M., Vicente D., Smolin A. et al., 2020/05/01. JAMA oncology, 6 (5) pp. 661-674. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E92D7568B2CF]
 
Glioma patient-reported outcome assessment in clinical care.
Tuleasca C., Knisely J., Leroy H.A., Hottinger A.F., Peciu-Florianu I., Levivier M., Reyns N., 2020/05. The Lancet. Oncology, 21 (5) pp. e230. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_17C0FE6C449F]
 
Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.
Cohen R., Vernerey D., Bellera C., Meurisse A., Henriques J., Paoletti X., Rousseau B., Alberts S., Aparicio T., Boukovinas I. et al., 2020/05. European journal of cancer, 130 pp. 63-71. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D4332D75C365]
 
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J., Subbiah V., Besse B., Moreno V., López R., Sala M.A., Peters S., Ponce S., Fernández C., Alfaro V. et al., 2020/05. The Lancet. Oncology, 21 (5) pp. 645-654. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2823CF0CC276]
 
Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays' and cross-validation with resections, in patients with, stage I-III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort.
Thunnissen E., Kerr K.M., Dafni U., Bubendorf L., Finn S.P., Soltermann A., Biernat W., Cheney R., Verbeken E., Warth A. et al., 2020/05. Modern pathology, 33 (5) pp. 792-801. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_20143D2EA518]
Oncologie : naviguer la pandémie de COVID-19 et garder le cap [Oncology: navigating the COVID-19 Pandemic and Steer the Course]
Zimmermann S., Dietrich P.Y., Michielin O., Betticher D., Peters S., 2020/04/29. Revue medicale suisse, 16 (N° 691-2) pp. 819-822. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0B2FC89C06E5]
Tumor response and outcome after reverse treatment for patients with synchronous colorectal liver metastasis: a cohort study.
Du Pasquier C., Roulin D., Bize P., Sempoux C., Rebecchini C., Montemurro M., Schäfer M., Halkic N., Demartines N., 2020/04/19. BMC surgery, 20 (1) p. 78. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_6C26AD0111F4]
LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma
Keskin T., Bakaric A., Waszyk P., Boulay G., Torsello M., Cornaz-Buros S., Chevalier N., Geiser T., Martin P., Volorio A. et al., 2020/04/14. Cell Reports.
[URN][DOI][WoS][Pmid][serval:BIB_69BFEDF2908B]
 
Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial.
Delaloge S., Piccart M., Rutgers E., Litière S., van 't Veer L.J., van den Berkmortel F., Brain E., Dudek-Peric A., Gil-Gil M., Gomez P. et al., 2020/04/10. Journal of clinical oncology, 38 (11) pp. 1186-1197. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E3334B715FAE]
 
Quantifying potential confounders of panel-based tumor mutational burden (TMB) measurement
Budczies Jan, Kazdal Daniel, Allgäuer Michael, Christopoulos Petros, Rempel Eugen, Pfarr Nicole, Weichert Wilko, Fröhling Stefan, Thomas Michael, Peters Solange et al., 2020/04. Lung Cancer, 142 pp. 114-119. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_86732A1E3A60]
LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma LIN28B Control of EWS-FLI1 Stability.
Keskin T., Bakaric A., Waszyk P., Boulay G., Torsello M., Cornaz-Buros S., Chevalier N., Geiser T., Martin P., Volorio A. et al., 2020/03/31. Cell reports, 30 (13) pp. 4567-4583.e5. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_EAA705D7C5B5]
 
Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.
Molina-Vila M.A., Stahel R.A., Dafni U., Jordana-Ariza N., Balada-Bel A., Garzón-Ibáñez M., García-Peláez B., Mayo-de-Las-Casas C., Felip E., Curioni Fontecedro A. et al., 2020/03. Journal of thoracic oncology, 15 (3) pp. 416-425. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0A96B7671FCB]
 
First-Line Selective Internal Radiation Therapy in Patients with Uveal Melanoma Metastatic to the Liver.
Ponti A., Denys A., Digklia A., Schaefer N., Hocquelet A., Knebel J.F., Michielin O., Dromain C., Duran R., 2020/03. Journal of nuclear medicine, 61 (3) pp. 350-356. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4FD86FE51A57]
 
Primary Sarcoma of the Lung - Prognostic Value of Clinicopathological Characteristics of 26 Cases.
Duran-Moreno J., Kokkali S., Ramfidis V., Salomidou M., Digklia A., Koumarianou A., Tomos P., Koufopoulos N., Vamvakaris I., Psychogiou E. et al., 2020/03. Anticancer research, 40 (3) pp. 1697-1703. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_15EF81B04AF1]
 
Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
Schmid S., Früh M., Peters S., 2020/03. The Lancet. Oncology, 21 (3) pp. 320-322. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_3BA14E3E28D1]
The isolation of cancer survivors.
Danesi G., Bourquin C., Stiefel F., Zaman K., Saraga M., 2020/03. European journal of cancer care, 29 (2) pp. e13194. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_8D04859E006C]
Journée du cancer : mobiliser autour de la prévention []
Peters S., Dietrich P.Y., 2020/02/19. Revue medicale suisse, 16 (682) pp. 382-383. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B68E3A035596]
 
Tout à coup elle a entendu des voix
Robert Julie, Blondet Fanny, Stravodimou Athina, Bouclin Thierry, Monti Matteo, 2020/02/11. Forum Médical Suisse ‒ Swiss Medical Forum.
[DOI][serval:BIB_DAB55DA6AB1E]
 
Development and implementation strategies of a nurse-led symptom self-management program in outpatient cancer centres: The Symptom Navi© Programme.
Bana M., Ribi K., Kropf-Staub S., Näf E., Schramm M.S., Zürcher-Florin S., Peters S., Eicher M., 2020/02. European journal of oncology nursing, 44 p. 101714. Peer-reviewed.
[DOI][Pmid][serval:BIB_2CE8D9A81F0D]
 
Management of recurrent and metastatic oral cavity cancer: Raising the bar a step higher.
Szturz P., Vermorken J.B., 2020/02/01. Oral oncology, 101 p. 104492. Peer-reviewed.
[DOI][Pmid][serval:BIB_CBE719CA5F22]
 
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with locally-advanced unresectable non-small-cell lung cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.
Park K., Vansteenkiste J., Lee K.H., Pentheroudakis G., Zhou C., Prabhash K., Seto T., Voon P.J., Tan DSW, Yang JCH et al., 2020/02. Annals of oncology, 31 (2) pp. 191-201. Peer-reviewed.
[DOI][Pmid][serval:BIB_C12CEF723BE2]
Oncologie [Advances in Oncology 2019]
Vernadou A., Ferahta N., Mederos N., Ferraro D., Dischl-Antonioni I., Diciolla A., Liapi A., Mosimann V., Latifyan S., Aedo-Lopez V. et al., 2020/01/15. Revue medicale suisse, 16 (676-7) pp. 72-77. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_66705C7E0EE3]
Oncologie [Advances in Oncology 2019]
Vernadou A., Ferahta N., Mederos N., Ferraro D., Dischl-Antonioni I., Diciolla A., Liapi A., Mosimann V., Latifyan S., Aedo-Lopez V. et al., 2020/01/15. Revue medicale suisse, 16 (676-7) pp. 72-77. Peer-reviewed.
[URN][Pmid][serval:BIB_7B31C4DA5F5B]
Imaging of tumour response to immunotherapy.
Dromain C., Beigelman C., Pozzessere C., Duran R., Digklia A., 2020/01/03. European radiology experimental, 4 (1) p. 2. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_152AC98411BD]
Biogenesis of HLA Ligand Presentation in Immune Cells Upon Activation Reveals Changes in Peptide Length Preference.
Marino F., Semilietof A., Michaux J., Pak H.S., Coukos G., Müller M., Bassani-Sternberg M., 2020. Frontiers in immunology, 11 p. 1981. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E06D274ABF64]
 
Cardiovascular safety of rapidly accelerated fibrosarcoma B-type and/or mitogen-activated extracellular signal-regulated kinase inhibitors: A mixed approach combining a meta-analysis and a pharmacovigilance disproportionality analysis.
Dolladille C., Font J., Bejan-Angoulvant T., Zaman K., Sassier M., Ezine E., Stefan A., Plane A.F., Legallois D., Milliez P. et al., 2020. Archives of cardiovascular diseases, 113 (6-7) pp. 420-432. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7CE8172A0C7F]
 
Do not de-escalate oncology care in oropharyngeal cancer routinely.
Szturz P., Vermorken J.B., 2020/01. Head & neck, 42 (1) pp. 143-144. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_60067256F5B4]
Effect of everolimus on multifocal micronodular pneumocyte hyperplasia in tuberous sclerosis complex.
Daccord C., Nicolas A., Demicheli R., Chehade H., Hottinger A.F., Beigelman C., Lazor R., 2020. Respiratory medicine case reports, 31 p. 101310. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D07C5F1D118C]
Follow-Up of Head and Neck Cancer Survivors: Tipping the Balance of Intensity.
Szturz P., Van Laer C., Simon C., Van Gestel D., Bourhis J., Vermorken J.B., 2020. Frontiers in oncology, 10 p. 688. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3FAFF518089A]
 
Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
Siebenhüner A., De Dosso S., Meisel A., Wagner A.D., Borner M., 2020. Oncology research and treatment, 43 (5) pp. 237-244. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FF92BBB469D2]
Multidisciplinary management of stage II-III gastric and gastro-oesophageal junction cancer.
Wagner A.D., Lordick F., Grabsch H.I., Terashima M., Terada M., Yoshikawa T., Boku N., Kataoka K., Smyth E.C., Mauer M. et al., 2020/01. European journal of cancer, 124 pp. 67-76. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_35163E169A37]
 
Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV<sup>+</sup> Cancers.
Galliverti G., Wullschleger S., Tichet M., Murugan D., Zangger N., Horton W., Korman A.J., Coussens L.M., Swartz M.A., Hanahan D., 2020/01. Cancer immunology research, 8 (1) pp. 131-145. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_04D464D7C6BB]
Paraneoplastic Cerebellar Ataxia Can Affect Prognosis in High-Grade Serous Ovarian Cancer: A Case Report.
Liapi A., Sarivalasis A., 2020. Case reports in oncology, 13 (2) pp. 1006-1012. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2EBF9B7A049D]
Predicting combinations of immunomodulators to enhance dendritic cell-based vaccination based on a hybrid experimental and computational platform.
Ahmed R., Crespo I., Tuyaerts S., Bekkar A., Graciotti M., Xenarios I., Kandalaft L.E., 2020. Computational and structural biotechnology journal, 18 pp. 2217-27. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2B3CB067B0E1]
Primary Care-Led Transition Clinics Hold Promise in Improving Care Transitions for Cancer Patients Facing Social Disparities: A Commentary.
Malebranche M., Sarivalasis A., Peters S., Mathevet P., Cornuz J., Bodenmann P., 2020. Journal of primary care & community health, 11 p. 2150132720957455. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_5CB413D626EE]
Radiomics Feature Activation Maps as a New Tool for Signature Interpretability.
Vuong D., Tanadini-Lang S., Wu Z., Marks R., Unkelbach J., Hillinger S., Eboulet E.I., Thierstein S., Peters S., Pless M. et al., 2020. Frontiers in oncology, 10 p. 578895. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_F93AA20EEB4E]
 
Recommendation for supportive care in patients receiving concurrent chemotherapy and radiotherapy for lung cancer.
De Ruysscher D., Faivre-Finn C., Nackaerts K., Jordan K., Arends J., Douillard J.Y., Ricardi U., Peters S., 2020/01. Annals of oncology, 31 (1) pp. 41-49. Peer-reviewed.
[DOI][Pmid][serval:BIB_7799A6933B37]
Relationship between pneumonitis induced by immune checkpoint inhibitors and the underlying parenchymal status: a retrospective study.
Pozzessere C., Bouchaab H., Jumeau R., Letovanec I., Daccord C., Bourhis J., Prior J.O., Peters S., Lazor R., Beigelman-Aubry C., 2020/01. ERJ open research, 6 (1). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_58E543FE8A79]
 
Sertoli-Leydig Cell Ovarian Tumors: Is Fertility or Endocrine-Sparing Surgery an Option upon Relapse?
Seidler S.J., Huber A., Nef J., Huber D.E., 2020. Case reports in oncology, 13 (2) pp. 935-940. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_2700C5F787AB]
 
Sixty spontaneous vertebral fractures after denosumab discontinuation in 15 women with early-stage breast cancer under aromatase inhibitors.
Gonzalez-Rodriguez E., Aubry-Rozier B., Stoll D., Zaman K., Lamy O., 2020/01. Breast cancer research and treatment, 179 (1) pp. 153-159. Peer-reviewed.
[DOI][Pmid][serval:BIB_8D0CD026EA9F]
2019
Impact of treatment decision algorithms on treatment costs in recurrent glioblastoma: a health economic study.
Panje C.M., Putora P.M., Hundsberger T., Hottinger A.F., Roelcke U., Pesce G., Herrmann E., Matter-Walstra K., 2019/12/02. Swiss medical weekly, 149 pp. w20153. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3F94BAF5F930]
Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.
Pillonel V., Dunet V., Hottinger A.F., Berthod G., Schiappacasse L., Peters S., Michielin O., Aedo-Lopez V., 2019/12/02. Journal for immunotherapy of cancer, 7 (1) p. 336. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9C48A9CE403D]
 
18F-FDG positive colorectal polyp mimicing metastasis of advanced melanoma treated with ipilimumab
Koukalová K., Lakomý R., Fabian P., Řehák Z., Szturz P., 2019/12/01. Nukleární medicína, 8 (4) pp. 76-79. Peer-reviewed.
[serval:BIB_4F37351EC7B9]
 
Definition of Synchronous Oligometastatic Non-Small Cell Lung Cancer-A Consensus Report.
Dingemans A.C., Hendriks LEL, Berghmans T., Levy A., Hasan B., Faivre-Finn C., Giaj-Levra M., Giaj-Levra N., Girard N., Greillier L. et al., 2019/12. Journal of thoracic oncology, 14 (12) pp. 2109-2119. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7217B3C47C1C]
 
Gender medicine and oncology: report and consensus of an ESMO workshop.
Wagner A.D., Oertelt-Prigione S., Adjei A., Buclin T., Cristina V., Csajka C., Coukos G., Dafni U., Dotto G.P., Ducreux M. et al., 2019/12/01. Annals of oncology, 30 (12) pp. 1914-1924. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C7C76EA90383]
 
Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.
Astorgues-Xerri L., Vázquez R., Odore E., Rezai K., Kahatt C., Mackenzie S., Bekradda M., Coudé M.M., Dombret H., Gardin C. et al., 2019/12. Leukemia & lymphoma, 60 (12) pp. 3067-3070. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_379C92028C87]
 
Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer.
Pérol M., Pavlakis N., Levchenko E., Platania M., Oliveira J., Novello S., Chiari R., Moran T., Mitry E., Nüesch E. et al., 2019/12. Lung cancer, 138 pp. 79-87. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_DC94C42CF26B]
 
A Phase I/II trial comparing autologous dendritic cell vaccine pulsed either with personalized peptides (PEP-DC) or with tumor lysate (OC-DC) in patients with advanced high-grade ovarian serous carcinoma.
Sarivalasis A., Boudousquié C., Balint K., Stevenson B.J., Gannon P.O., Iancu E.M., Rossier L., Martin Lluesma S., Mathevet P., Sempoux C. et al., 2019/11/26. Journal of translational medicine, 17 (1) p. 391. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_502B05978E61]
CD56 as a marker of an ILC1-like population with NK cell properties that is functionally impaired in AML.
Salomé B., Gomez-Cadena A., Loyon R., Suffiotti M., Salvestrini V., Wyss T., Vanoni G., Ruan D.F., Rossi M., Tozzo A. et al., 2019/11/26. Blood advances, 3 (22) pp. 3674-3687. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4BC26C680B22]
 
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B., Harrington K.J., Greil R., Soulières D., Tahara M., de Castro G., Psyrri A., Basté N., Neupane P., Bratland Å. et al., 2019/11/23. Lancet, 394 (10212) pp. 1915-1928. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_30CA2114242B]
 
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.
Hellmann M.D., Paz-Ares L., Bernabe Caro R., Zurawski B., Kim S.W., Carcereny Costa E., Park K., Alexandru A., Lupinacci L., de la Mora Jimenez E. et al., 2019/11/21. The New England journal of medicine, 381 (21) pp. 2020-2031. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9D16DE496DBE]
 
Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study.
Lamarca A., Ronot M., Moalla S., Crona J., Opalinska M., Lopez Lopez C., Pezzutti D., Najran P., Carvhalo L., Bezerra ROF et al., 2019/11/15. Clinical cancer research, 25 (22) pp. 6692-6699. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_9AC787A38DB8]
 
Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers.
Labidi-Galy S.I., de La Motte Rouge T., Derbel O., Wolfer A., Kalbacher E., Olivier T., Combes J.D., Heimgartner-Hu K., Tredan O., Guevara H. et al., 2019/11. Gynecologic oncology, 155 (2) pp. 262-269. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FC4CA8A34E82]
 
EP617 Second line treatment in metastatic uterine pecoma
Liapi A, Herrera Gómez RG, Bisig B, Brouland JP, Herrera F, Mathevet P, Sarivalasis A, 2019/11. ePoster.
[DOI][WoS][serval:BIB_1F9D59473327]
 
EP648 Subungual metastasis of an endometrial carcinoma
Vernadou A, Hastir D, Sarivalasis A, 2019/11. ePoster.
[DOI][WoS][serval:BIB_952B5F0D28A0]
 
EP753 Single centre experience with anti-PD1 therapy in gynaecologic cancers
Ozdemir B, Dromain C, Sarivalasis A, 2019/11. ePoster.
[DOI][WoS][serval:BIB_2C77F5B23839]
 
EP974 Review of three cases of high grade serous ovarian cancer associated with cerebellar atrophy and acute inflammatory demyelinating polyneuropathy
Liapi A, Herrera Gómez RG, Sakeliades E, Sarivalasis A, 2019/11. ePoster.
[DOI][WoS][serval:BIB_CAA07C21D1DF]
 
Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials.
Davidson M., Wagner A.D., Kouvelakis K., Nanji H., Starling N., Chau I., Watkins D., Rao S., Peckitt C., Cunningham D., 2019/11. European journal of cancer, 121 pp. 40-47. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_AD8C86867293]
 
Spatial and Temporal Heterogeneity of Panel-Based Tumor Mutational Burden in Pulmonary Adenocarcinoma: Separating Biology From Technical Artifacts.
Kazdal D., Endris V., Allgäuer M., Kriegsmann M., Leichsenring J., Volckmar A.L., Harms A., Kirchner M., Kriegsmann K., Neumann O. et al., 2019/11. Journal of thoracic oncology, 14 (11) pp. 1935-1947. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_E1CA5C54D324]
 
Value of Tumor Growth Rate (TGR) as an Early Biomarker Predictor of Patients' Outcome in Neuroendocrine Tumors (NET)-The GREPONET Study.
Lamarca A., Crona J., Ronot M., Opalinska M., Lopez Lopez C., Pezzutti D., Najran P., Carvhalo L., Franca Bezerra R.O., Borg P. et al., 2019/11. The oncologist, 24 (11) pp. e1082-e1090. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_FC7684CF2AE5]
Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma.
Cristina V., Herrera-Gómez R.G., Szturz P., Espeli V., Siano M., 2019/10/30. International journal of molecular sciences, 20 (21). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D6D634194460]
Intratumoral CD8<sup>+</sup> T cells with stem cell-like properties: Implications for cancer immunotherapy.
Held W., Siddiqui I., Schaeuble K., Speiser D.E., 2019/10/23. Science translational medicine, 11 (515) pp. eaay6863. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_2890415E8A72]
 
Appraising the Tail of the Survival Curve in the Era of PD-1/PD-L1 Checkpoint Blockade.
Zimmermann S., Peters S., 2019/10/01. JAMA oncology, 5 (10) pp. 1403-1405. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4DB804EB26DC]
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data.
Schmid S., Klingbiel D., Aebi S., Goldhirsch A., Mamot C., Munzone E., Nolè F., Oehlschlegel C., Pagani O., Pestalozzi B. et al., 2019/09/10. BMC cancer, 19 (1) p. 902. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7B45E5A3F16D]
 
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F., Sofiya L., Sykiotis G.P., Lamine F., Maillard M., Fraga M., Shabafrouz K., Ribi C., Cairoli A., Guex-Crosier Y. et al., 2019/09. Nature reviews. Clinical oncology, 16 (9) pp. 563-580. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7F8DDEE8DA1E]
Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma.
Pertesi M., Vallée M., Wei X., Revuelta M.V., Galia P., Demangel D., Oliver J., Foll M., Chen S., Perrial E. et al., 2019/09. Leukemia, 33 (9) pp. 2324-2330. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2DE401BF6410]
 
Optimizing panel-based tumor mutational burden (TMB) measurement.
Budczies J., Allgäuer M., Litchfield K., Rempel E., Christopoulos P., Kazdal D., Endris V., Thomas M., Fröhling S., Peters S. et al., 2019/09/01. Annals of oncology, 30 (9) pp. 1496-1506. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_D315A8B5404A]
 
Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis.
Ascierto P.A., Bifulco C., Palmieri G., Peters S., Sidiropoulos N., 2019/09. The Journal of molecular diagnostics, 21 (5) pp. 756-767. Peer-reviewed.
[DOI][Pmid][serval:BIB_9D4DDEC2C2EE]
A Phase Ib Study of the Combination of Personalized Autologous Dendritic Cell Vaccine, Aspirin, and Standard of Care Adjuvant Chemotherapy Followed by Nivolumab for Resected Pancreatic Adenocarcinoma—A Proof of Antigen Discovery Feasibility in Three Patients
Bassani-Sternberg Michal, Digklia Antonia, Huber Florian, Wagner Dorothea, Sempoux Christine, Stevenson Brian J., Thierry Anne-Christine, Michaux Justine, Pak HuiSong, Racle Julien et al., 2019/08/08. Frontiers in Immunology, 10 p. 1832. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0144F5D289B5]
 
Current status of immune checkpoint inhibition in early-stage NSCLC.
Vansteenkiste J., Wauters E., Reymen B., Ackermann C.J., Peters S., De Ruysscher D., 2019/08/01. Annals of oncology, 30 (8) pp. 1244-1253. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_F6160457AF7A]
 
EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer.
Früh M., Peters S., 2019/08/01. Annals of oncology, 30 (8) pp. 1190-1192. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7FD503F6638D]
 
F-18-FDG PET metabolic-to-morphological volume ratio predicts PD-L1 tumour expression and response to PD-1 blockade in non-small-cell lung cancer.
Jreige M., Letovanec I., Chaba K., Renaud S., Rusakiewicz S., Cristina V., Peters S., Krueger T., de Leval L., Kandalaft L.E. et al., 2019/08. European journal of nuclear medicine and molecular imaging, 46 (9) pp. 1859-1868. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4F575C6723CE]
 
Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis.
Dafni U., Tsourti Z., Vervita K., Peters S., 2019/08. Lung cancer, 134 pp. 127-140. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_C3ECA1D23C4B]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University